DAWN
Day One Biopharmaceuticals, Inc. · Healthcare · Biotechnology
At close
$10.59
−$0.01 (−0.14%) Close
Pre-market $10.60 +$0.01 (+0.14%) 11:04 PM ET
Prev close $10.60
Open $10.59
Day high $10.59
Day low $10.59
Volume 281
Avg vol 2,415,362
Mkt cap
$1.09B
P/E ratio
-10.18
FY Revenue
$158.18M
EPS
-1.04
Gross Margin
89.12%
Sector
Healthcare
AI report sections
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals shows strong positive price momentum over the last 1–6 months with multiple bullish technical signals, even though the 12‑month return remains slightly negative. At the same time, fundamentals are under pressure with declining revenue, deeply negative margins, and substantial cash burn, partially offset by a sizable equity base and low balance-sheet leverage. Short interest is elevated in both percentage of float and days to cover, while recent news around the Mersana acquisition has been consistently positive in tone and pipeline-focused.
AI summarized at 10:08 AM ET, 2026-01-13
AI summary scores
INTRADAY: 68 SWING: 74 LONG: 39
Volume vs average
Intraday (cumulative)
−15% (Below avg)
Vol/Avg: 0.85×
RSI
44.87 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.02 Signal: 0.01
Short-Term
-0.13 (Weak)
MACD: 0.17 Signal: 0.30
Long-Term
-0.09 (Weak)
MACD: 0.60 Signal: 0.69
Intraday trend score 46.32

Latest news

DAWN 12 articles Positive: 6 Neutral: 0 Negative: 0
Positive GlobeNewswire Inc. • Na
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

Day One Biopharmaceuticals reported strong 2025 financial results with OJEMDA net product revenues of $155.4 million (172% YoY growth) and Q4 revenues of $52.8 million. The company reaffirmed its 2026 U.S. OJEMDA revenue guidance of $225-$250 million and announced the acquisition of Mersana Therapeutics to expand its pipeline with Emi-Le for adenoid cystic carcinoma treatment.

DAWN OJEMDA pediatric cancer biopharmaceutical clinical trials revenue growth Mersana Therapeutics acquisition ADC (antibody drug conjugate)
Sentiment note

Strong commercial momentum with 172% YoY revenue growth for OJEMDA, 181% prescription growth, successful pipeline expansion through Mersana acquisition, positive clinical data updates, and solid cash position of $441.1 million. Company reaffirmed optimistic 2026 revenue guidance and demonstrated improving operational efficiency with reduced net losses.

Positive Benzinga • Globe Newswire
Day One Completes Acquisition of Mersana Therapeutics

Day One Biopharmaceuticals (NASDAQ: DAWN) has successfully completed its acquisition of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition adds Emi-Le, a novel antibody-drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma, to Day One's clinical pipeline, expanding its presence in adult oncology while maintaining focus on rare cancers.

DAWN MRSN acquisition merger biopharmaceutical ADC oncology rare cancer
Sentiment note

Successfully completed strategic acquisition that expands pipeline with a novel ADC asset, strengthens market position in oncology, and provides access to treatment for rare cancer with unmet medical needs. CEO commentary emphasizes transformative potential and business growth.

Positive Benzinga • Vandana Singh
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for up to $285 million, expanding its oncology pipeline with a focus on developing antibody-drug conjugates targeting cancers, particularly in pediatric and triple-negative breast cancer treatments.

DAWN MRSN acquisition oncology antibody-drug conjugates cancer treatment pediatric cancer
Sentiment note

Expanding pipeline through strategic acquisition, showing strong financial position with $451.6 million in cash, and increasing product revenue for Ojemda

Positive GlobeNewswire Inc. • Day One Biopharmaceuticals
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Day One Biopharmaceuticals announced it will acquire Mersana Therapeutics for approximately $129 million, expanding its oncology portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), which shows early anti-tumor activity in adenoid cystic carcinoma treatment.

DAWN MRSN acquisition oncology antibody-drug conjugate cancer treatment merger
Sentiment note

Acquiring a promising therapeutic asset that expands portfolio and potential for patient impact, with no additional financing required

Positive GlobeNewswire Inc. • Day One Biopharmaceuticals
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6 million for OJEMDA, a 310% increase from Q2 2024. The company expects full-year 2025 revenue of $140-$150 million and continues advancing its clinical pipeline, including the FIREFLY-2 trial for pediatric low-grade glioma treatment.

DAWN OJEMDA tovorafenib pediatric cancer RAF inhibitor clinical trials
Sentiment note

Strong revenue growth (310% YoY), expanding product prescriptions, ongoing clinical trials, and positive financial outlook with $453.1 million in cash reserves

Positive GlobeNewswire Inc. • Kuick Research
Global Cancer Antibody Drug Conjugates Market Size Forecast 2030

The global cancer antibody drug conjugates (ADCs) market is expected to surpass $50 billion by 2030, driven by the approval of 16 ADC drugs and over 500 ADCs in clinical trials. The market has experienced substantial growth, reaching over $7 billion in the first half of 2024, with ADCs offering improved efficacy and lower toxicity compared to traditional cancer treatments.

DAWN cancer antibody drug conjugates market size clinical trials approvals
Sentiment note

Day One's exclusive licensing deal with MabCare Therapeutics for the development and commercialization of MTX-13 is an example of the strategic alliances and partnerships driving the growth of the ADC market.

Unknown Zacks Investment Research • Zacks Equity Research
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.

CGEN ANVS ALXO DAWN
Unknown GlobeNewswire Inc. • Day One Biopharmaceuticals, Inc.
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024

DAWN Clinical Study
Unknown GlobeNewswire Inc. • Day One Biopharmaceuticals, Inc.
Day One Announces Sale of Priority Review Voucher for $108 Million

BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).

DAWN Financing Agreements
Unknown GlobeNewswire Inc. • Day One Biopharmaceuticals, Inc.
Day One Reports First Quarter 2024 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

DAWN Earnings Releases and Operating Results
Unknown GlobeNewswire Inc. • Day One Biopharmaceuticals, Inc.
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co

DAWN Health Clinical Study Calendar of Events
Unknown GlobeNewswire Inc. • Day One Biopharmaceuticals, Inc.
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024

DAWN Earnings Releases and Operating Results
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal